Acacia description, usages, side effects, indications, overdosage, supplying and lots more!

Acacia

Nelco Laboratories, Inc.
Nelco Laboratories, Inc.

Allergenic Extract

FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

WARNING

Diagnostic and therapeutic allergenic extracts are intended to be administered by a physician who is an allergy specialist and experienced in allergenic diagnostic testing and immunotherapy and the emergency care of anaphylaxis.

This product should not be injected intravenously. Deep subcutaneous routes have been safe. Sensitive patients may experience severe anaphylactic reactions resulting in respiratory obstruction, shock, coma and/or death. (See Adverse Reactions)

Serious adverse reactions should be reported to Nelco Laboratories immediately and a report filed to: MedWatch, The FDA Medical Product Problem Reporting Program, at 5600 Fishers Lane, Rockville, Md. 20852-9787, call 1-800-FDA-1088.

Extreme caution should be taken when using allergenic extracts for patients who are taking beta-blocker medications. In the event of a serious adverse reaction associated with the use of allergenic extracts, patients receiving beta-blockers may not be responsive to epinephrine or inhaled brochodialators.(1) (See Precautions)

Allergenic extracts should be used with caution for patients with unstable or steroid-dependent asthma or underlying cardiovascular disease. (See Contraindications)

DESCRIPTION

Allergenic extracts are sterile solutions consisting of the extractable components from various biological sources including pollens, inhalants, molds, animal epidermals and insects. Aqueous extracts are prepared using cocas fluid containing NaCl 0.5%, NaHCO3 0.0275%, WFI, preservative 0.4% Phenol. Glycerinated allergenic extracts are prepared with cocas fluid and glycerin to produce a 50% (v/v) allergenic extract. Allergenic Extracts are supplied as concentrations designated as protein nitrogen units (PNU) or weight/volume (w/v) ratio. Standardized extracts are designated in Bioequivalent Allergy Units (BAU) or Allergy Units (AU). (See product insert for standardized extracts)

For diagnostic purposes, allergenic extracts are to be administered by prick-puncture or intradermal routes. Allergenic extracts are administered subcutaneously for immunotherapy injections.

CLINICAL PHARMACOLOGY

The pharmacological action of allergenic extracts used diagnostically is based on the liberation of histamine and other substances when the allergen reacts with IgE antibodies attached to the mast cells. When allergenic extracts are used for immunotherapy, the effect is an increase in immunoglobulin G (IgG) and an increased T suppresser lymphocyte which interferes with the allergic response.(2) With repeated administration of allergenic extracts changes develop in regards to IgG and IgE production and mediator-releasing cells. The histamine release response is reduced in some patients.

INDICATIONS AND USAGE

Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity.

Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again.

CONTRAINDICATIONS

Allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of type 1 allergic disease is made based on skin testing and the benefits of treatment outweigh the risks of an adverse reaction during testing or treatment. Allergenic extracts are not indicated for use in patients who are not clinically allergic or who are not skin reactive to an allergen. Allergenic extracts should be discontinued or the concentration of potency substantially reduced in patients who experience unacceptable adverse reactions.

WARNINGS

DO NOT INJECT INTRAVENOUSLY.

Epinephrine 1:1000 should be available.

Concentrated extracts must be diluted with sterile diluent prior to first use on a patient for treatment or intradermal testing. All concentrates of glycerinated allergenic extracts have the ability to cause serious local and systemic reactions including death in sensitive patients. Sensitive patients may experience severe anaphylactic reactions resulting in respiratory obstruction, shock, coma and /or death.(4) (See Adverse Reactions) An allergenic extract should be temporarily withheld from patients or the dose of the extract adjusted downward if any of the following conditions exist: (1) Severe symptoms of rhinitis and/or asthma (2) Infections or flu accompanied by fever and (3) Exposure to excessive amounts of clinically relevant allergen prior to a scheduled injection. When switching patients to a new lot of the same extract the initial dose should be reduced 3/4 so that 25% of previous dose is administered.

PRECAUTIONS

GENERAL: Epinephrine 1:1000 should be available as well as personnel trained in administering emergency treatment. Allergenic Extracts are not intended for intravenous injections. For safe and effective use of allergenic extracts, sterile diluents, sterile vials, sterile syringes should be used and aseptic precautions observed when making a dilution and/or administering the allergenic extract injection. A sterile tuberculin syringe graduated in 0.1 ml units to measure each dose for the prescribed dilution should be used. To reduce the risk of an occurrence of adverse reactions, begin with a careful personal history plus a physical exam. Confirm your findings with scratch or intradermal skin testing.

Standardized extracts are those labeled in AU/ml units or BAU/ml units. Standardized extracts are not interchangeable with extracts previously labeled as wt/vol or PNU/ml. Before administering a standardized extract, read the accompanying insert contained with standardized extracts.

Information for Patients: All concentrates of allergenic extracts have the ability to cause serious local and systemic reactions including death in sensitive patients. Patients should be informed of this risk prior to skin testing and immunotherapy. Patients should be instructed to recognize adverse reaction symptoms that may occur and to report all adverse reactions to a physician. Patients should be instructed to remain in the office for 30 minutes during testing using allergenic extracts and at least 30 minutes after therapeutic injections using allergenic extracts.

DRUG INTERACTIONS: Some drugs may affect the reactivity of the skin; patients should be instructed to avoid medications, particularly antihistamines and sympathomimetic drugs, for at least 24 hours prior to skin testing. Antihistamines and Hydroxyzine can significantly inhibit the immediate skin test reactions as they tend to neutralize or antagonize the action of histamine.(3) This effect has been primarily documented when testing was performed within 1 to 2 hours after drug ingestion. Partial inhibition of the skin test reaction had been observed for longer periods. Epinephrine injection inhibits the immediate skin test reactions for several hours. Patients on delayed absorption antihistamine tablets should be free of such medication for 48 hours before testing. Patients using Astemizole (Hismanal) may experience prolonged suppression and should be free from such medication for up to 6 to 8 weeks prior to testing. Refer to package insert from an applicable long acting antihistamine manufacturer for additional information.

Extreme caution should be taken when using allergenic extracts on patients who are taking beta-blockers. Patients on non-selective beta blockers may be more reactive to allergens given for testing or treatment and may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.

Carcinogenesis, mutagenesis, impairment of fertility:

Long term studies in animals have not been conducted with allergenic extracts to determine their potential carcinogenicity, mutagenicity or impairment of fertility.

Pregnancy: Category C: Animal reproduction studies have not been conducted with Allergenic Extracts. It is not known whether allergenic extracts can cause fetal harm when administered to pregnant women or can affect reproduction capacity. Allergenic extracts should be given to pregnant women only if clearly needed.

Nursing Mothers: It is not known whether this drug appears in human milk. Because many drugs are detected in human milk, caution should be exercised when Allergenic Extracts are administered to a nursing woman. There are no current studies on extract components in human milk, or their effect on the nursing infant.

Pediatric Use: Allergenic extracts have been used in children over two years of age.(5)

ADVERSE REACTIONS

Adverse systemic reactions usually occur within minutes and consist primarily of allergic symptoms such as: generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, itching of nose and throat, breathlessness, dyspnea, coughing, hypotension and marked perspiration. Less commonly, nausea, emesis, abdominal cramps, diarrhea and uterine contractions may occur. Severe reactions may cause anaphylaxis or shock and loss of consciousness and rarely death.

The treatment of systemic allergic reactions is dependent upon the system complex. Antihistamines may offer relief of recurrent urticaria, associated skin reactions and gastrointestinal symptoms. Corticosteroids may provide benefit if symptoms are prolonged or recurrent. (See Overdose section)

Local Reactions consisting of erythema, itching, swelling tenderness and sometimes pain may occur at the injection site. These reactions may appear within a few minutes to hours and persist for several days. Local cold applications and oral antihistamines may be effective treatment. For marked and prolonged local reactions the use of antihistamines or anti-inflammatory medications may be dictated. Serious adverse reactions should be reported to Nelco Laboratories immediately and a report can be filed to: MedWatch, The FDA Medical Product Problem Reporting Program, at 5600 Fishers Lane, Rockville, MD 20852-9787, call 1-800-FDA-1088.

OVERDOSAGE

Overdose can cause both local and systemic reactions. An overdose may be prevented by careful observation and questioning of the patient about the previous injection.

If systemic or anaphylactic reaction, does occur, apply a tourniquet above the site of injection and inject intramuscularly or subcutaneously 0.3 to 0.5ml of 1:1000 Epinephrine Hydrochloride into the opposite arm. The dose may be repeated in 5-10 minutes if necessary. Loosen the tourniquet at least every 10 minutes. The Epinephrine Hydrochloride 1:1000 dose for infants to 2 years is 0.05 to 0.1 ml, for children 2 to 6 years it is 0.15 ml, for children 6-12 years it is 0.2 ml.

Patients unresponsive to Epinephrine may be treated with Theophylline. Studies on asthmatic subjects reveal that plasma concentrations of Theophylline of 5 to 20 µg/ml are associated with therapeutic effects. Toxicity is particularly apparent at concentrations greater than 20 µg/ml. A loading dose of Aminophylline of 5.8 mg/kg intravenously followed by 0.9 mg/kg per hour results in plasma concentrations of approximately 10 µg/ml for patients not previously receiving theophylline. (Mitenko and Ogilive, Nicholoson and Chick,1973)

Other beta-adrenergic drugs such as Isoproterenol, Isoetharine, or Albuterol may be used by inhalation. The usual dose to relieve broncho-constriction in asthma is 0.5 ml of the 0.5% solution for Isoproterenol HCl. The Albuterol inhaler delivers approximately 90 mcg of Albuterol from the mouthpiece. The usual dosage for adults and children would be two inhalations repeated every 4-6 hours. Isoetharine supplied in the Bronkometer unit delivers approximately 340 mcg Isoetharine. The average dose is one to two inhalations. Respiratory obstruction not responding to parenteral or inhaled bronchodilators may require oxygen, intubation and the use of life support systems.

DOSAGE AND ADMINISTRATION

General Precautions

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permits.

The dosage of allergenic extracts is dependent upon the purpose of the administration. Allergenic extracts can be administered for diagnostic use or for therapeutic use.

When allergenic extracts are administered for diagnostic use, the dosage is dependent upon the method used. Two methods commonly used are scratch testing and intradermal testing. Both types of tests result in a wheal and flare response at the site of the test which usually develops rapidly and may be read in 20-30 minutes.

Diagnostic Use : Scratch Testing Method

Scratch testing is considered a simple and safe method although less sensitive than the intradermal test. Scratch testing can be used to determine the degree of sensitivity to a suspected allergen before using the intradermal test. This combination lessens the severity of response to an allergen which can occur in a very sensitive patient.

The most satisfactory testing site is the patient's back or volar surface of the arms from the axilla to 2.5 or 5cm above the wrist, skipping the anti-cubital space. If using the back as a testing site, the most satisfactory area are from the posterior axillary fold to 2.5 cm from the spinal column, and from the top of the scapula to the lower rib margins.

Allergenic extracts for diagnostic use are to be administered in the following manner: To scratch surface of skin, use a circular scarifier. Do not draw blood. Tests sites should be 4 cm apart to allow for wheal and flare reaction. 1-30 scratch tests may be done at a time. A separate sterile scratch instrument is to be used on each patient to prevent transmission of homologous serum hepatitis or other infectious agents from one patient to another.

The recommended usual dosage for Scratch testing is one drop of allergen applied to each scratch site. Do not let dropper touch skin. Always apply a control scratch with each test set. Sterile Diluent (for a negative control) is used in exactly the same way as an active test extract. Histamine may be used as a positive control. Scratch or prick test sites should be examined at 15 and 30 minutes. To prevent excessive absorption, wipe off antigens producing large reactions as soon as the wheal appears. Record the size of the reaction.

Interpretation of Scratch Test

Skin tests are graded in terms of the wheal and erythema response noted at 10 to 20 minutes. Wheal and erythema size may be recorded by actual measurement as compared with positive and negative controls. A positive reaction consists of an area of erythema surrounding the scarification that is larger than the control site. For uniformity in reporting reactions, the following system is recommended. (6)

REACTION SYMBOL CRITERIA
Negative - No wheal. Erythema absent or very slight (not more than 1 mm diameter).
One Plus + Wheal absent or very slight erythema present (not more than 3 mm diameter).
Two Plus ++ Wheal not more than 3mm or erythema not more than 5mm diameter.
Three Plus +++ Wheal between 3mm and 5mm diameter, with erythema. Possible pseudopodia and itching.
Four Plus ++++ A larger reaction with itching and pain.

Diagnostic Use: Intradermal Skin Testing Method

Do not perform intradermal test with allergens which have evoked a 2+ or greater response to a Scratch test. Clean test area with alcohol, place sites 5 cm apart using separate sterile tuberculin syringe and a 25 gauge needle for each allergen. Insert needle tip, bevel up, into intracutaneous space. Avoid injecting into blood vessel, pull back gently on syringe plunger, if blood enters syringe change position of needle. The recommended dosage and range for intradermal testing is 0.05 ml of not more than 100 pnu/ml or 1:1000 w/v (only if puncture test is negative) of allergenic extract. Inject slowly until a small bleb is raised. It is important to make each bleb the same size.

Interpretation of Intradermal Test:

The patient's reaction is graded on the basis of size of wheal and flare as compared to control. Use 0.05 ml sterile diluent as a negative control to give accurate interpretation. The tests may be accurately interpreted only when the saline control site has shown a negative response. Observe patient for at least 30 minutes. Tests can be read in 15-20 minutes. Edema, erythema and presence of pseudopods, pain and itching may be observed in 4 plus reactions. For uniformity in reporting reactions the following system is recommended. (6)

REACTION SYMBOL CRITERIA
Negative - No increase in size of bleb since injection. No erythema.
One Plus + An increase in size of bleb to a wheal not more than 5mm diameter, with associated erythema.
Two Plus ++ Wheal between 5mm and 8mm diameter with erythema.
Three Plus +++ Wheal between 8mm and 12mm diameter with erythema and possible pseudopodia and itching or pain.
Four Plus ++++ Any larger reaction with itch and pain, and possible diffuse blush of the skin surrounding the reaction area.

Therapeutic Use: Recommended dosage & range

Check the listed ingredients to verify that it matches the prescription ordered. When using a prescription set, verify the patient's name and the ingredients listed with the prescription order. Assess the patient's physical and emotional status prior to giving as injection. Do not give injections to patients who are in acute distress. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Dosage of allergenic extracts is a highly individualized matter and varies according to the degree of sensitivity of the patient, his clinical response and tolerance to the extract administered during the early phases of an injection regimen. The dosage must be reduced when transferring a patient from non-standardized or modified extract to standardized extract. Any evidence of a local or generalized reaction requires a reduction in dosage during the initial stages of immunotherapy as well as during maintenance therapy. After therapeutic injections patients should be observed for at least 20 minutes for reaction symptoms.

SUGGESTED DOSAGE SCHEDULE

The following schedule may act as a guide. This schedule has not been proven to be safe or effective. Sensitive patients may begin with smaller doses of weaker solutions and the dosage increments can be less.

STRENGTH DOSE VOLUME
Vial #1 1 0.05
1:100,000 w/v 2 0.10
10 pnu/ml 3 0.15
1 AU/ml 4 0.20
1 BAU/ml 5 0.30
6 0.40
7 0.50
Vial #2 8 0.05
1:10,000 w/v 9 0.10
100 pnu/ml 10 0.15
10 AU/ml 11 0.20
10 BAU/ml 12 0.30
13 0.40
14 0.50
Vial #3 15 0.05
1:1,000 w/v 16 0.10
1,000 pnu/ml 17 0.15
100 AU/ml 18 0.20
100 BAU/ml 19 0.30
20 0.40
21 0.50
Vial #4 22 0.05
1:100 w/v 23 0.07
10,000 pnu/ml 24 0.10
1,000 AU/ml 25 0.15
1,000 BAU/ml 26 0.20
27 0.25
Maintenance Refill 28 0.25
1:100 w/v 29 0.25
10,000 pnu/ml 30 0.25
1,000 AU/ml 31 0.25
1,000 BAU/ml 32 0.25
subsequent doses 33 0.25

Preparation Instructions:

All dilutions may be made using sterile buffered diluent. The calculation may be based on the following ratio:

Volume desired x Concentration desired = Volume needed x Concentration available.

Example 1: If a 1:10 w/v extract is available and it is desired to use a 1:1,000 w/v extract substitute as follows:

Vd x Cd = Vn x Ca

10ml x 0.001 = Vn x 0.1

0.1 ml = Vn

Using a sterile technique, remove 0.10 ml of extract from the 1:10 vial and place it into a vial containing 9.90 ml of sterile diluent. The resulting ratio will be a 10 ml vial of 1:1,000 w/v.

Example 2: If a 10,000 pnu/ml extract is available and it is desired to use a 100 pnu/ml extract substitute as follows:

10ml x 100 = Vn x 10,000

0.1 ml = Vn

Using a sterile technique, remove 0.10 ml of extract from the 10,000 pnu/ml vial and place it into a vial containing 9.90 ml of sterile diluent. The resulting concentration will be a 10 ml vial of 100 pnu/ml.

Example 3: If a 10,000 AU/ml or BAU/ml extract is available and it is desired to use a 100 AU/ml or BAU/ml extract substitute as follows: Vd x Cd = Vn x Ca

10ml x 100 = Vn x 10,000

0.1 ml = Vn

Using a sterile technique, remove 0.10 ml of extract from the 10,000 AU/ml or BAU/ml vial and place it into a vial containing 9.90 ml of sterile diluent. The resulting concentration will be 10ml vial of 100 AU/ml or BAU/ml.

Intervals between doses: The optimal interval between doses of allergenic extract has not been definitely established. The amount of allergenic extract is increased at each injection by not more than 50%-100% of the previous amount and the next increment is governed by the response to the last injection. There are three generally accepted methods of pollen hyposensitizing therapy.

1. PRESEASONAL

Treatment starts each year 6 to 8 weeks before onset of seasonal symptoms. Maximal dose reached just before symptoms are expected. Injections discontinued during and following season until next year.

2. CO-SEASONAL

Patient is first treated during season with symptoms. Low initial doses are employed to prevent worsening of condition. This is followed by an intensive schedule of therapy (i.e. injections given 2 to 3 times per week). Fewer Allergists are resorting to this Co-seasonal therapy because of the availability of more effective, symptomatic medications that allow the patient to go through a season relatively symptom free.

3. PERENNIAL

Initially this is the same as pre seasonal. The allergen is administered twice weekly or weekly for about 20 injections to achieve the maximum tolerated dose. Then, maintenance therapy may be administered once a week or less frequently.

Duration of Treatment: The usual duration of treatment has not been established. A period of two or three years of injection therapy constitutes an average minimum course of treatment.

HOW SUPPLIED

Allergenic extracts are supplied with units listed as: Weight/volume (W/V), Protein Nitrogen Units (PNU/ml), Allergy Units (AU/ml) or Bioequivalent Allergy Units (BAU/ml).

Sizes:

Diagnostic Scratch: 5 ml dropper application vials

Diagnostic Intradermal: 5 ml or 10 ml vials.

Therapeutic Allergens: 5 ml, 10 ml, 50 ml multiple dose vials.

STORAGE

The expiration date of allergen extracts is listed on the container label. Store extracts upon arrival at 2° to 8°C and keep them in this range during office use.

WARRANTY: We warrant that this product was prepared and tested according to the standards of the FDA and is true to label. Because of biological differences in individuals and because allergenic extracts are manufactured to be potent and because we have no control over the conditions of use, we cannot and do not warrant either a good effect or against an ill effect following use.

REFERENCES

1 Jacobs, Robert L., Geoffrey W.Rake,Jr., et.al. Potentiated Anaphylaxis in Patients with Drug-induced Beta-adrenergic Blockade. J.Allergy & Clin. Immunol., 68(2): 125-127. August 1981.

2 Ishizaka,K.: Cellular Events in the IgE Antibody Response. Adv. in Immuno. 23:50-75, 1976.

3. Lockey, R.F., Bukantz, S.C., Allergen Immunotherapy. New York,NY: Marcel Dekker Inc., 1991.

4. Reid,M.J., Lockey,R.F., Turkeltaub,P.C., Platts-Mills,T.A.E., Survey of fatalities from skin testing and immunotherapy 1985-1989. Journal of Allergy Clin. Immunol. 92 (1): 6-15, July 1993.

5. Murray, A.B., Ferguson, A., Morrison, B., The frequency and severity of cat allergy vs dog allergy in atopic children. J. Allergy Clin. Immunolo: 72, 145-9, 1983.

6. Lockey, R.F., Bukantz, S.C., Allergen Immunotherapy. New York,NY: Marcel Dekker Inc., 1991.

CONTAINER LABELING

CONTAINER LABELINGCONTAINER LABELINGCONTAINER LABELINGCONTAINER LABELING

Acacia

Acacia INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2452
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ACACIA BAILEYANA POLLEN ACACIA BAILEYANA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2452-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2452-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2452-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2452-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Red Alder

Red Alder INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2460
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ALNUS RUBRA POLLEN ALNUS RUBRA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2460-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2460-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2460-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2460-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Tag Alder

Tag Alder INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2468
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ALNUS INCANA SUBSP. RUGOSA POLLEN ALNUS INCANA SUBSP. RUGOSA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2468-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2468-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2468-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2468-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


White Alder

White Alder INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2476
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ALNUS RHOMBIFOLIA POLLEN ALNUS RHOMBIFOLIA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
water
SODIUM BICARBONATE
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2476-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2476-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2476-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2476-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Arizona Ash

Arizona Ash INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2484
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
FRAXINUS VELUTINA POLLEN FRAXINUS VELUTINA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2484-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2484-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2484-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2484-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Oregon Ash

Oregon Ash INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2492
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
FRAXINUS LATIFOLIA POLLEN FRAXINUS LATIFOLIA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2492-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2492-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2492-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2492-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


White Ash

White Ash INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2500
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
FRAXINUS AMERICANA POLLEN FRAXINUS AMERICANA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2500-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2500-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2500-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2500-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Aspen

Aspen INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2508
Route of Administration SUBCUTANEOUS DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
POPULUS TREMULOIDES POLLEN POPULUS TREMULOIDES POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2508-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2508-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2508-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2508-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Bayberry

Bayberry INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2516
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
MORELLA CERIFERA POLLEN MORELLA CERIFERA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2516-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2516-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2516-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2516-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


American Beech

American Beech INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2524
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
FAGUS GRANDIFOLIA POLLEN FAGUS GRANDIFOLIA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2524-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2524-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2524-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2524-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Beefwood/Australian Pine

Beefwood/Australian Pine INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2532
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
CASUARINA EQUISETIFOLIA POLLEN CASUARINA EQUISETIFOLIA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2532-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2532-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2532-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2532-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Birch

Birch INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2540
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
BETULA NIGRA POLLEN BETULA NIGRA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2540-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2540-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2540-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2540-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Black Birch

Black Birch INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2548
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
BETULA LENTA POLLEN BETULA LENTA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2548-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2548-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2548-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2548-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


White Birch

White Birch INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2556
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
BETULA POPULIFOLIA POLLEN BETULA POPULIFOLIA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2556-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2556-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2556-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2556-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Box Elder

Box Elder INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2564
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ACER NEGUNDO POLLEN ACER NEGUNDO POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2564-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2564-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2564-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2564-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Mountain Cedar

Mountain Cedar INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2572
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
JUNIPERUS ASHEI POLLEN JUNIPERUS ASHEI POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2572-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2572-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2572-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2572-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Red Cedar

Red Cedar INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2580
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
JUNIPERUS VIRGINIANA POLLEN JUNIPERUS VIRGINIANA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2580-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2580-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2580-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2580-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Salt Cedar

Salt Cedar INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2588
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
TAMARIX GALLICA POLLEN TAMARIX GALLICA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM BICARBONATE
SODIUM CHLORIDE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2588-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2588-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2588-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2588-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Eastern Cottonwood

Eastern Cottonwood INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2596
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
POPULUS DELTOIDES POLLEN POPULUS DELTOIDES POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2596-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2596-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2596-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2596-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Fremont Cottonwood

Fremont Cottonwood INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2604
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
POPULUS FREMONTII POLLEN POPULUS FREMONTII POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2604-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2604-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2604-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2604-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


West Cottonwood

West Cottonwood INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2612
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
POPULUS DELTOIDES SUBSP. MONILIFERA POLLEN POPULUS DELTOIDES SUBSP. MONILIFERA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2612-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2612-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2612-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2612-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Arizona Cypress

Arizona Cypress INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2620
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
CUPRESSUS ARIZONICA POLLEN CUPRESSUS ARIZONICA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2620-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2620-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2620-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2620-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Bald Cypress

Bald Cypress INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2628
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
TAXODIUM DISTICHUM POLLEN TAXODIUM DISTICHUM POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2628-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2628-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2628-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2628-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


American Elm

American Elm INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2636
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ULMUS AMERICANA POLLEN ULMUS AMERICANA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2636-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2636-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2636-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2636-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Cedar Elm

Cedar Elm INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2644
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ULMUS CRASSIFOLIA POLLEN ULMUS CRASSIFOLIA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2644-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2644-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2644-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2644-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Chinese Elm

Chinese Elm INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2652
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ULMUS PUMILA POLLEN ULMUS PUMILA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2652-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2652-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2652-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2652-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Eucalyptus

Eucalyptus INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2660
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
EUCALYPTUS GLOBULUS POLLEN EUCALYPTUS GLOBULUS POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2660-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2660-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2660-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2660-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Hazelnut

Hazelnut INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2668
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
CORYLUS AMERICANA POLLEN CORYLUS AMERICANA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2668-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2668-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2668-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2668-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Shagbark Hickory

Shagbark Hickory INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2676
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
CARYA OVATA POLLEN CARYA OVATA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2676-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2676-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2676-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2676-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


White Hickory

White Hickory INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2684
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
CARYA ALBA POLLEN CARYA ALBA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2684-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2684-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2684-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2684-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


One Seed Juniper

One Seed Juniper INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2692
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
JUNIPERUS MONOSPERMA POLLEN JUNIPERUS MONOSPERMA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2692-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2692-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2692-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2692-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Pinchot Juniper

Pinchot Juniper INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2700
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
JUNIPERUS PINCHOTII POLLEN JUNIPERUS PINCHOTII POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2700-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2700-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2700-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2700-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Rocky Mountain Juniper

Rocky Mountain Juniper INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2708
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
JUNIPERUS SCOPULORUM POLLEN JUNIPERUS SCOPULORUM POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2708-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2708-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2708-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2708-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Utah Juniper

Utah Juniper INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2716
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
JUNIPERUS OSTEOSPERMA POLLEN JUNIPERUS OSTEOSPERMA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2716-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2716-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2716-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2716-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Western Juniper

Western Juniper INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2724
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
JUNIPERUS OCCIDENTALIS POLLEN JUNIPERUS OCCIDENTALIS POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2724-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2724-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2724-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2724-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Linden

Linden INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2732
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
TILIA AMERICANA POLLEN Tilia americana pollen 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2732-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2732-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2732-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2732-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Black Locust

Black Locust INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2740
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ROBINIA PSEUDOACACIA POLLEN ROBINIA PSEUDOACACIA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2740-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2740-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2740-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2740-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Mango Blossom

Mango Blossom INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2748
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
MANGIFERA INDICA POLLEN MANGIFERA INDICA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2748-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2748-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2748-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2748-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Coast Maple

Coast Maple INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2756
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ACER MACROPHYLLUM POLLEN ACER MACROPHYLLUM POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2756-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2756-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2756-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2756-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Red Maple

Red Maple INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2764
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ACER RUBRUM POLLEN ACER RUBRUM POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2764-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2764-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2764-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2764-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Silver Maple

Silver Maple INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2772
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ACER SACCHARINUM POLLEN ACER SACCHARINUM POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2772-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2772-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2772-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2772-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Sugar Maple

Sugar Maple INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2780
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ACER SACCHARUM POLLEN ACER SACCHARUM POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2780-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2780-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2780-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2780-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Melaleuca Pollen

Melaleuca Pollen INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2788
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
MELALEUCA QUINQUENERVIA POLLEN MELALEUCA QUINQUENERVIA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2788-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2788-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2788-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2788-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Mesquite

Mesquite INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2796
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
PROSOPIS JULIFLORA POLLEN PROSOPIS JULIFLORA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2796-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2796-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2796-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2796-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


White Mulberry

White Mulberry INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2804
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
MORUS ALBA POLLEN MORUS ALBA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2804-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2804-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2804-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2804-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Red Mulberry

Red Mulberry INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2812
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
MORUS RUBRA POLLEN MORUS RUBRA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2812-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2812-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2812-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2812-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Mulberry

Mulberry INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2820
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
BROUSSONETIA PAPYRIFERA POLLEN BROUSSONETIA PAPYRIFERA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2820-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2820-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2820-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2820-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Black Oak

Black Oak INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2828
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
QUERCUS VELUTINA POLLEN QUERCUS VELUTINA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2828-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2828-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2828-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2828-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Burr Oak

Burr Oak INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2836
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
QUERCUS MACROCARPA POLLEN QUERCUS MACROCARPA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2836-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2836-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2836-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2836-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


California Black Oak

California Black Oak INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2844
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
QUERCUS KELLOGGII POLLEN QUERCUS KELLOGGII POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2844-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2844-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2844-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2844-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


California Live Oak

California Live Oak INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2852
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
QUERCUS AGRIFOLIA POLLEN QUERCUS AGRIFOLIA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2852-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2852-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2852-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2852-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Gambil Oak

Gambil Oak INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2860
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
QUERCUS GAMBELII POLLEN QUERCUS GAMBELII POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2860-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2860-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2860-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2860-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Red Oak

Red Oak INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2868
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
QUERCUS RUBRA POLLEN QUERCUS RUBRA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2868-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2868-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2868-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2868-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


California Valley White Oak

California Valley White Oak INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2876
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
QUERCUS LOBATA POLLEN QUERCUS LOBATA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2876-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2876-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2876-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2876-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Virginia Live Oak

Virginia Live Oak INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2884
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
QUERCUS VIRGINIANA POLLEN QUERCUS VIRGINIANA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2884-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2884-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2884-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2884-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Water Oak

Water Oak INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2892
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
QUERCUS NIGRA POLLEN QUERCUS NIGRA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2892-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2892-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2892-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2892-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


White Oak

White Oak INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2900
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
QUERCUS ALBA POLLEN QUERCUS ALBA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2900-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2900-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2900-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2900-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Olive Pollen

Olive Pollen INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2908
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
OLEA EUROPAEA POLLEN OLEA EUROPAEA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2908-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2908-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2908-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2908-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Orange Pollen

Orange Pollen INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2916
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
CITRUS SINENSIS POLLEN CITRUS SINENSIS POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2916-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2916-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2916-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2916-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Queen Palm

Queen Palm INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2924
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
SYAGRUS ROMANZOFFIANA POLLEN Syagrus romanzoffiana pollen 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2924-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2924-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2924-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2924-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Pecan Pollen

Pecan Pollen INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2932
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
CARYA ILLINOINENSIS POLLEN CARYA ILLINOINENSIS POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2932-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2932-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2932-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2932-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Pepper Tree Pollen

Pepper Tree Pollen INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2940
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
SCHINUS MOLLE POLLEN SCHINUS MOLLE POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2940-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2940-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2940-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2940-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 2009-12-04


Loblolly Pine

Loblolly Pine INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2948
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
PINUS TAEDA POLLEN PINUS TAEDA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
water
PHENOL
SODIUM CHLORIDE
SODIUM BICARBONATE

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2948-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2948-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2948-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2948-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Longleaf Pine

Longleaf Pine INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2956
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
PINUS PALUSTRIS POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2956-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2956-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2956-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2956-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Ponderosa Pine

Ponderosa Pine INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2964
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
PINUS PONDEROSA POLLEN PINUS PONDEROSA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2964-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2964-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2964-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2964-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Slash Pine

Slash Pine INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2972
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
PINUS ELLIOTTII POLLEN PINUS ELLIOTTII POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2972-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2972-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2972-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2972-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Scrub Pine

Scrub Pine INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2980
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
PINUS VIRGINIANA POLLEN PINUS VIRGINIANA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2980-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2980-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2980-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2980-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


White Pine

White Pine INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2988
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
PINUS STROBUS POLLEN PINUS STROBUS POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2988-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2988-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2988-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2988-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Western White Pine

Western White Pine INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-2996
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
PINUS MONTICOLA POLLEN PINUS MONTICOLA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-2996-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-2996-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-2996-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-2996-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Yellow Pine

Yellow Pine INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3004
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
PINUS ECHINATA POLLEN PINUS ECHINATA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3004-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3004-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3004-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3004-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Lombardy Poplar

Lombardy Poplar INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3012
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
POPULUS NIGRA POLLEN POPULUS NIGRA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3012-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3012-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3012-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3012-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


White Poplar

White Poplar INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3020
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
POPULUS ALBA POLLEN POPULUS ALBA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3020-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3020-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3020-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3020-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Privet

Privet INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3028
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
LIGUSTRUM VULGARE POLLEN LIGUSTRUM VULGARE POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3028-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3028-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3028-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3028-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Russian Olive

Russian Olive INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3036
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ELAEAGNUS ANGUSTIFOLIA POLLEN ELAEAGNUS ANGUSTIFOLIA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3036-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3036-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3036-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3036-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Sweet Gum

Sweet Gum INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3044
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
LIQUIDAMBAR STYRACIFLUA POLLEN LIQUIDAMBAR STYRACIFLUA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3044-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3044-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3044-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3044-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


East Sycamore

East Sycamore INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3052
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
PLATANUS OCCIDENTALIS POLLEN PLATANUS OCCIDENTALIS POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3052-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3052-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3052-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3052-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


West Sycamore

West Sycamore INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3060
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
PLATANUS RACEMOSA POLLEN PLATANUS RACEMOSA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3060-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3060-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3060-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3060-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Black Walnut

Black Walnut INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3068
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
JUGLANS NIGRA POLLEN JUGLANS NIGRA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3068-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3068-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3068-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3068-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


California Black Walnut

California Black Walnut INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3076
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
JUGLANS CALIFORNICA POLLEN JUGLANS CALIFORNICA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3076-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3076-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3076-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3076-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


English Walnut

English Walnut INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3084
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
JUGLANS REGIA POLLEN JUGLANS REGIA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3084-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3084-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3084-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3084-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Black Willow

Black Willow INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3092
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
SALIX NIGRA POLLEN SALIX NIGRA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3092-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3092-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3092-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3092-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Arroyo Willow

Arroyo Willow INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3100
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
SALIX LASIOLEPIS POLLEN SALIX LASIOLEPIS POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3100-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3100-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3100-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3100-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Pussy Willow

Pussy Willow INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3108
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
SALIX DISCOLOR POLLEN SALIX DISCOLOR POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3108-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3108-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3108-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3108-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Poplar

Poplar INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3116
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
POPULUS DELTOIDES POLLEN POPULUS DELTOIDES POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3116-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3116-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3116-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3116-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


Balsam Poplar

Balsam Poplar INJECTION, SOLUTION

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:36987-3124
Route of Administration INTRADERMAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
POPULUS BALSAMIFERA SUBSP. TRICHOCARPA POLLEN POPULUS BALSAMIFERA SUBSP. TRICHOCARPA POLLEN 0.1 g

Inactive Ingredients

Ingredient Name Strength
SODIUM CHLORIDE
SODIUM BICARBONATE
water
PHENOL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:36987-3124-1 5 in 1 VIAL, MULTI-DOSE
2 NDC:36987-3124-2 10 in 1 VIAL, MULTI-DOSE
3 NDC:36987-3124-3 30 in 1 VIAL, MULTI-DOSE
4 NDC:36987-3124-4 50 in 1 VIAL, MULTI-DOSE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA102192 1972-08-29


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.